ICCVAM evaluated the validation status of five in vitro test methods proposed as replacements for the rabbit pyrogen test for assessing the potential pyrogenicity (i.e., ability to induce fever) of pharmaceuticals and other products. ICCVAM recommended that none of these test methods can be considered a complete replacement for the rabbit pyrogen test for the detection of Gram-negative endotoxin. However, they can be considered for use to detect Gram-negative endotoxin in human parenteral drugs on a case-by-case basis, subject to validation for each specific product to demonstrate equivalence to the rabbit pyrogen test, in accordance with applicable U.S. Federal regulations. When used in this manner, these methods should be able to reduce the number of animals used for pyrogenicity testing. All applicable Federal agencies, including the U.S. Food and Drug Administration (FDA), accepted or endorsed the ICCVAM recommendations.
Test Method Evaluation Report (May 2008) including ICCVAM recommendations
In 2012, the FDA issued “Guidance for Industry: Pyrogens and Endotoxin Testing: Questions and Answers.” This document is addressed to biological product, drug, and device manufacturers and is meant to clarify FDA’s current position on pyrogen testing and acceptance criteria. The guidance discusses approaches such as pooling samples for testing that could reduce animal use and states that in vitro monocyte activation pyrogen tests similar to tests evaluated by ICCVAM may be used in lieu of the rabbit pyrogen test or the bacterial endotoxin test given appropriate product-specific validation.
Five in vitro pyrogen test methods were evaluated by ICCVAM in response to a submission by the European Centre for the Validation of Alternative Methods (now known as EURL ECVAM):
The test methods measure cytokine levels (either IL-1β or IL-6) from human blood cells or a human monocytoid cell line. Increased cytokine release is used as a biomarker of a pyrogenic response. The reliability and relevance of each test method was evaluated with pyrogen-free parenteral pharmaceuticals spiked with different concentrations of an endotoxin standard. Using a prediction model developed based on in vivo rabbit data, results from each test method were compared to the ''true status'' of the samples.
A draft ICCVAM background review document and draft ICCVAM test method recommendations on the test methods were discussed at a public meeting of an independent scientific peer review Panel convened in February 2007.
ICCVAM considered the comments of the Panel (contained in the Peer Review Panel Report), the general public, and the Scientific Advisory Committee on Alternative Toxicological Methods as they prepared the final background review document and final test method recommendations.
ICCVAM’s evaluation of the validation status of the in vitro pyrogen test methods, as well as ICCVAM’s recommendations for current uses and limitations for each test method and recommendations for standardized protocols, future studies, and performance standards are included in the ICCVAM Test Method Evaluation Report: Validation Status of Five In Vitro Test Methods Proposed for Assessing Potential Pyrogenicity of Pharmaceuticals and Other Products (NIH Publication Number 08-6392).
The recommendations were communicated to Federal agencies in letters from Dr. Samuel H. Wilson, Acting Director, NIEHS, to each agency head. Links to these letters and the responses from the agency heads or designees can be found below.
The MM6 cell line is a human monocytic cell line originally described by Professor H.W.L. Ziegler-Heitbrock at the Institute for Immunology, University of Munich, Germany (Ziegler‑Heitbrock et al., Int J Cancer 41:456-461, 1988). The MM6 cell line may be purchased from the German Collection of Microorganisms and Cell Cultures by individuals working at non-profit organizations. Prior to transaction, a legal agreement must be reached with Professor Ziegler-Heitbrock stating that the cells will be used for research purposes only. Any contract research organization or pharmaceutical company wanting to obtain the MM6 cell line must contact Professor Ziegler-Heitbrock to negotiate a fee for provision and a royalty payment per batch of product tested. Professor Ziegler-Heitbrock may be contacted at: Professor Dr. H.W.L. Ziegler-Heitbrock, University of Leicester, Dept. of Microbiology, University Road, Leicester LE1 9HN, United Kingdom, e-mail: email@example.com.